文献速递乳腺癌支持与姑息治疗

早期三阴性乳腺癌老年患者接受辅助紫杉烷+蒽环类方案与紫杉烷类方案的重大心血管不良事件:SEER-Medicare研究

Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
PubMed 文献 · Eur J Cancer · 2023-11-11

基于SEER-Medicare数据库纳入2010至2015年诊断的2215例66岁及以上早期三阴性乳腺癌女性,比较辅助蒽环类+紫杉烷(ATAX)与紫杉烷类(TAX)方案的重大心血管不良事件(MACE)。ATAX组发生心力衰竭的几率低于TAX组(OR 0.63,95%CI 0.45-0.88,p<0.01);发生MACE者中两组总生存与癌症特异性生存无差异。

要点

  • ATAX组发生心力衰竭的几率低于TAX组(OR 0.63,95%CI 0.45-0.88,p<0.01)。
  • 控制传统危险因素后,ATAX组发生急性心肌梗死、脑血管意外或潜在致死性心律失常的几率与TAX组相比无统计学显著差异。
  • 发生MACE者中,TAX组与ATAX组的总生存和癌症特异性生存无差异。

核心结论

  • 在有早期三阴性乳腺癌的老年女性中,接受辅助ATAX方案化疗与重大不良心血管事件风险增加无关。
  • 对于发生心脏事件者,接受TAX方案与ATAX方案者的生存无差异。
  • 作者提出,其他因素包括其他化疗毒性应作为老年女性(淋巴结阴性或1-3枚阳性)中既往观察到的ATAX较TAX总生存更差的潜在病因加以研究。

研究设计与样本

  • 利用监测、流行病学和最终结果(SEER)-Medicare数据库,识别2010至2015年诊断的66岁及以上早期三阴性乳腺癌女性(N=2215)。
  • 按辅助化疗方案(化疗 vs 无化疗;ATAX vs TAX)比较患者和临床特征。
  • 采用逻辑回归估计比值比(OR)和95%置信区间(CI),Kaplan-Meier生存曲线估计3年总生存(OS)和癌症特异性生存(CSS),Cox比例风险模型分析OS和CSS并控制患者和肿瘤特征。
  • MACE定义为急性心肌梗死、心力衰竭、潜在致死性心律失常和脑血管事件;发生心脏死亡的患者很少,因此分析中排除。

主要发现

  • 2215例患者中,大多数(n=1334;60.26%)接受TAX方案,ATAX方案为n=881;39.78%。
  • 控制传统危险因素后,接受ATAX方案者发生急性心肌梗死、脑血管意外(CVA)或潜在致死性心律失常的几率与接受TAX方案者相比无统计学显著差异。
  • 发生MACE的患者中,接受TAX方案与ATAX方案者的OS或CSS无差异。
  • 接受ATAX方案者发生心力衰竭的几率低于接受TAX方案者(OR 0.63,95%CI 0.45-0.88,p<0.01)。
  • 发生MACE且年龄>76岁者与发生MACE且年龄66-75岁者相比OS更差(HR 1.67,95%CI 1.07-2.62,p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancer (TNBC) is more aggressive as compared to other subtypes of breast cancer with characteristic metastatic patterns and a poor prognosis. The standard of care for early-stage TNBC is historically anthracycline and taxane-based chemotherapy (ATAX). Despite the effectiveness of this regimen, anthracyclines carry a small but important risk of cardiotoxicity, which is specifically a concern in the older population. This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with ATAX compared to taxane-based chemotherapy (TAX). METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we identified women aged 66 and older with TNBC diagnosed between 2010 and 2015 (N = 2215). We compared patient and clinical characteristics according to adjuvant chemotherapy regimen (chemotherapy versus no chemotherapy and ATAX versus TAX). Logistic regression was performed to estimate the odds ratios (OR) and 95% confidence intervals (CIs), Kaplan-Meier survival curves were generated to estimate three-year overall survival (OS) and cancer specific survival (CSS). Cox proportional hazards models were used to analyze OS and CSS while controlling for patient and tumor characteristics. MACE was defined as acute myocardial infarction, heart failure, potentially fatal arrhythmia, and cerebral vascular incidence. Few patients experienced a cardiac death and therefore this was excluded in the analysis. RESULTS: Of the 2215 patients in our cohort, most patients (n = 1334; 60.26%) received TAX compared to ATAX (n = 881; 39.78%). Patients who received ATAX were not statistically significantly more likely than those who received TAX to experience acute myocardial infarction, cerebral vascular accident (CVA), or potentially fatal arrhythmia when controlling for traditional risk factors. Among patients who experienced MACE, there was no difference in OS or CSS in patients who received TAX vs ATAX. Patients who received ATAX were less likely to develop heart failure than those who received TAX (OR 0.63, 95% CI [0.45-0.88], p < 0.01). Patients who developed MACE and who were > 76 years old had worse OS compared to those who experienced MACE and were age 66-75 years old (HR 1.67, 95% CI [1.07-2.62], p = 0.02). CONCLUSION: Among older women with TNBC, receipt of adjuvant chemotherapy with ATAX was not associated with increased risk of major adverse cardiac events. For those who experienced a cardiac event, there was no difference in survival amongst those who received TAX vs ATAX. Other factors including additional chemotherapy toxicities should be investigated as a potential etiology for the inferior OS previously observed with ATAX vs TAX in older women with node negative or 1-3 positive lymph nodes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roy S, Lakritz S, Schreiber AR, et al. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study. Eur J Cancer. 2023. PMID: 38000217. doi:10.1016/j.ejca.2023.113426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。